SHANGHAI KAIBAO has obtained the drug registration certificate for Phlegm-Heat Clearing Capsules
SHANGHAI KAIBAO recently obtained the "Drug Registration Certificate" for Phlegm-Heat Clearing Capsules issued by the National Medical Products Administration. This drug is an exclusive product of the company, mainly used for clearing heat, resolving phlegm, and detoxifying. Indications include symptoms such as mild fever, cough, and sore throat caused by wind-heat lung disease and novel coronavirus infection
According to the Zhitong Finance APP, SHANGHAI KAIBAO (300039.SZ) announced that the company recently received the "Drug Registration Certificate" for Phlegm Heat Clearing Capsules issued by the National Medical Products Administration. Phlegm Heat Clearing Capsules are one of the main products in the company's Phlegm Heat Clearing series and are an exclusive variety of the company. Their functions and indications include: clearing heat, resolving phlegm, and detoxifying. They are used for wind-heat lung disease characterized by symptoms such as fever, aversion to wind, cough, phlegm production, sore throat, runny nose, and dry mouth. This time, the National Medical Products Administration granted the "Drug Registration Certificate," adding the indication "can be used for fever, cough, sore throat, etc. caused by mild cases in the routine treatment of novel coronavirus infection."
